Evaluate the expected performance of Lilly (LLY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Eli Lilly and Company discovers ... it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC ...

Until now, the main options for women in this category have been UCB's Evenity (romosozumab) or Eli Lilly's Forsteo (teriparatide), with older generic bisphosphonates such as alendronic acid used ...

Eli Lilly’s PTH-based osteoporosis therapy Forteo (teriparatide) is also used off-label in some hypoparathyroidism patients and, while Ascendis Pharma’s TransCon PTH (palopegteriparatide ...

He's also a former group vice president at Eli Lilly and later a vice president ... recombinant DNA (rDNA)-derived Humalog, rGlucagon and Forteo. Humalog, an injectable, fast-acting insulin ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...